Decoy Therapeutics (DCOY)
NASDAQ:DCOY
Want to see DCOY full AI Analyst Report?
Top Page
Decoy Therapeutics
(NASDAQ:DCOY)
Select Model
Select Model
Rating:43Neutral
Price Target:
$5.50
▼(-5.34% Downside)
Action:Reiterated
Date:06/11/26
The score is primarily held down by weak financial performance (no revenue, ongoing losses and cash burn, and shrinking equity). Technicals also remain unfavorable with the stock trading below major moving averages, while valuation is difficult to support due to negative earnings and no dividend. The Nasdaq compliance event is a modest positive but does not offset the core financial and trend risks.
Positive Factors
Low leverage / no debt
Zero reported debt gives the company structural financial flexibility, lowering interest burden and preserving capacity to raise targeted capital for R&D. Over 2–6 months this reduces solvency risk and allows management to prioritize program funding rather than debt service.
Negative Factors
Pre-revenue business model
Being pre-revenue leaves the firm dependent on external financing rather than operating cash flow. Over the medium term this limits visibility into commercial viability, increases investor dependence on development milestones, and raises execution risk for long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / no debt
Zero reported debt gives the company structural financial flexibility, lowering interest burden and preserving capacity to raise targeted capital for R&D. Over 2–6 months this reduces solvency risk and allows management to prioritize program funding rather than debt service.
Read all positive factors
Decoy Therapeutics (DCOY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.25M
Dividend YieldN/A
Average Volume (3M)356.88K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue GrowthN/A
EPS Growth86.68%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding531,968
10 Day Avg. Volume434,140
30 Day Avg. Volume356,875
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-1.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.55
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Decoy Therapeutics Business Overview & Revenue Model
Company Description
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthe...
Decoy Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -8.52M | -8.52M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -13.02M | -12.51M | -5.57M | -12.53M | -22.97M | -12.75M |
| Net Income | -13.03M | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
Balance Sheet | ||||||
| Total Assets | 8.42M | 11.06M | 3.02M | 6.59M | 14.65M | 40.83M |
| Cash, Cash Equivalents and Short-Term Investments | 7.82M | 10.71M | 2.43M | 5.90M | 12.11M | 29.21M |
| Total Debt | 0.00 | 0.00 | 221.87K | 289.64K | 0.00 | 0.00 |
| Total Liabilities | 4.55M | 5.17M | 1.51M | 1.30M | 4.27M | 2.11M |
| Stockholders Equity | 3.88M | 5.89M | 1.51M | 5.29M | 10.38M | 38.72M |
Cash Flow | ||||||
| Free Cash Flow | -6.53M | -4.83M | -4.53M | -12.85M | -19.10M | -10.20M |
| Operating Cash Flow | -6.53M | -4.83M | -4.53M | -12.85M | -17.60M | -10.20M |
| Investing Cash Flow | 764.74K | 764.74K | 0.00 | 0.00 | -1.50M | 0.00 |
| Financing Cash Flow | 11.79M | 12.34M | 1.06M | 6.64M | 1.99M | 28.30M |
Decoy Therapeutics Technical Analysis
Negative
5.81
Price Trends
6.09
Negative
7.12
Negative
18.70
Negative
Market Momentum
-0.08
Positive
44.39
Neutral
26.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCOY, the sentiment is Negative. The current price of 5.81 is below the 20-day moving average (MA) of 6.83, below the 50-day MA of 6.09, and below the 200-day MA of 18.70, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 44.39 is Neutral, neither overbought nor oversold. The STOCH value of 26.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCOY.
Decoy Therapeutics Risk Analysis
Decoy Therapeutics disclosed 46 risk factors in its most recent earnings report. Decoy Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Decoy Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.39M | -0.03 | -63.03% | ― | ― | 88.07% | |
45 Neutral | $1.29M | ― | ― | ― | -1.81% | -217.37% | |
43 Neutral | $3.25M | -0.24 | -139.55% | ― | ― | 86.68% | |
| ― | $2.82M | -0.27 | -168.95% | ― | ― | 84.00% | |
| ― | $4.02M | -0.07 | -263.57% | ― | -61.81% | 99.68% |
* Healthcare Sector Average
DCOY
Decoy Therapeutics
5.88
-183.12
-96.89%
BDRX
Biodexa Pharmaceuticals
2.98
-36.84
-92.52%
QCLS
Q/C Technologies
3.87
-11.11
-74.17%
SCNI
Scinai Immunotherapeutics
0.35
-1.92
-84.71%
OGEN
Oragenics
0.61
-3.76
-86.04%
ONCO
Onconetix
1.08
-203.92
-99.47%
Decoy Therapeutics Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
Decoy Therapeutics Sets 2026 Annual Shareholder Meeting Date
Neutral
May 19, 2026
On May 12, 2026, Decoy Therapeutics Inc.’s board set July 14, 2026, as the date for its 2026 Annual Meeting of Stockholders and designated May 22, 2026, as the record date for determining which investors may receive notice and vote. The comp...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split
Positive
Apr 2, 2026
Decoy Therapeutics has regained compliance with Nasdaq’s minimum bid price requirement after a period of deficiency that began with a notice on December 31, 2025, when its shares traded below $1.00 for 30 consecutive business days. Following...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.